Last reviewed · How we verify
Tdap Vaccine Administration
Tdap vaccine stimulates the immune system to produce antibodies and cellular immunity against tetanus toxoid, diphtheria toxoid, and acellular pertussis antigens.
Tdap vaccine stimulates the immune system to produce antibodies and cellular immunity against tetanus toxoid, diphtheria toxoid, and acellular pertussis antigens. Used for Prevention of tetanus, Prevention of diphtheria, Prevention of pertussis (whooping cough).
At a glance
| Generic name | Tdap Vaccine Administration |
|---|---|
| Also known as | BOOSTRIX, Tetanus-diphtheria-acellular pertussis |
| Sponsor | Institute of Arthritis Research |
| Drug class | vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxins from Clostridium tetani and Corynebacterium diphtheriae, along with purified acellular components of Bordetella pertussis. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize these pathogens if encountered naturally.
Approved indications
- Prevention of tetanus
- Prevention of diphtheria
- Prevention of pertussis (whooping cough)
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fatigue or malaise
- Headache
- Muscle aches
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy (PHASE4)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (PHASE2)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tdap Vaccine Administration CI brief — competitive landscape report
- Tdap Vaccine Administration updates RSS · CI watch RSS
- Institute of Arthritis Research portfolio CI